<code id='66A8C29750'></code><style id='66A8C29750'></style>
    • <acronym id='66A8C29750'></acronym>
      <center id='66A8C29750'><center id='66A8C29750'><tfoot id='66A8C29750'></tfoot></center><abbr id='66A8C29750'><dir id='66A8C29750'><tfoot id='66A8C29750'></tfoot><noframes id='66A8C29750'>

    • <optgroup id='66A8C29750'><strike id='66A8C29750'><sup id='66A8C29750'></sup></strike><code id='66A8C29750'></code></optgroup>
        1. <b id='66A8C29750'><label id='66A8C29750'><select id='66A8C29750'><dt id='66A8C29750'><span id='66A8C29750'></span></dt></select></label></b><u id='66A8C29750'></u>
          <i id='66A8C29750'><strike id='66A8C29750'><tt id='66A8C29750'><pre id='66A8C29750'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:3
          JUUL store sign -- health coverage from STAT
          Stephanie Keith/Getty Images

          Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes.

          Beginning in 2018, Juul executives, including the company’s CEO, discussed six- and seven-figure partnerships with civil rights organizations, one of which would have seen it send as much as $7 million to Sharpton’s group, according to internal emails and documents that were released this week as part of a legal settlement with the state of North Carolina.

          advertisement

          It’s not clear how much the company ultimately spent on the partnerships.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Study suggests Covid rebound is far more common with Paxlovid than without
          Study suggests Covid rebound is far more common with Paxlovid than without

          AdobeAsmallandpreliminarystudypublishedMondayseemstoindicatethatpatientsreceivingthedrugPaxlovidaref

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

          AlastairGrant/APLONDON— AstraZenecasaidThursdayitwouldpurchasetheFrenchfirmAmolytPharmainadealworthu